Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves Perrigo ANDA for Lansoprazole capsules
The company has begun the shipment of the product, which is bioequivalent to Novartis’ Prevacid OTC 24 hour capsules (15mg) and is indicated for the treatment of frequent
The company has begun the shipment of the product, which is bioequivalent to Novartis’ Prevacid OTC 24 hour capsules (15mg) and is indicated for the treatment of frequent
The company requires a strategic partner, additional funding, and interferon alpha-2b raw material support so as to begin any such trial. Helix, a developer of biopharmaceutical drug candidates
The Clopidogrel Tablets USP, 75mg are available in bottle count sizes of 30, 90 and 500, and tablets of 300mg strength are available in blister packs of 30’s
VitaGreens is a totally vegetarian nutrient-packed whole food formula that has been proven to improve overall health and quality of life throughout the body, claims the company. Each
The Dotmatics platform is a fully optimized suite of programs designed to make research data readily accessible and useful. The company’s suite of solutions are used to manage
The model-based approach links drug process and product engineering to product quality and performance in the human body. Pfizer senior research fellow, keynote speaker Ravi Shanker said it
The randomized, open-label study is designed to evaluate the safety and efficacy of the novel combination therapy. The multicenter trial will enroll a total of 100 patients in
The AlpVision’s patented Fingerprint technology is used in the partnership, which enables brand owners in the pharmaceutical industry to track and validate mass produced products manufactured in a
The antineoplastic agent of the topoisomerase I inhibitor class, in combination with 5-fluorouracil and leucovorin, is indicated for patients with metastatic carcinoma of the colon or rectum whose
The Phase 3 study is a randomized-withdrawal placebo-controlled trial included three phases: an open-label phase, during which the optimized 100-250mg two times per day dose of tapentadol ER